Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Events

21 Nov 2022

Wonderland 2022 Recap: Algernon Pharmaceuticals

Algernon Pharmaceuticals was the Headline Sponsor for Wonderland: Miami 2022, ; presenting their work on DMT for stroke...

By Microdose

Events

18 Nov 2022

Wonderland 2022 Review: MindBio Therapeutics

At Wonderland's Microdosing with LSD panel, Justin Hanka and Dr....

By Microdose

Events

31 Oct 2022

Microdose Announces Sponsors For Wonderland 2022

It’s an honor for Microdose to announce our line-up of top-notch sponsors for Wonderland 2022....

By Microdose

Events

27 Oct 2022

Microdose Announces Ninnion Therapeutics as Wonderland 2022 Platinum Sponsor

Microdose announces Ninnion Therapeutics as a Platinum Sponsor for Wonderland: Miami 2022....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Events

26 Oct 2022

Microdose Announces MindBio Therapeutics as Wonderland 2022 Platinum Sponsor

MindBio Therapeutics will be presenting at Wonderland 2022 as a key Platinum Sponsor...

By Microdose

Industry

24 Oct 2022

Top Reasons to be at Wonderland 2022 (Part 2)

Wonderland 2021 successfully established the event as the go-to industry gathering....

By Microdose

Industry

20 Oct 2022

Microdose Announces Algernon Pharmaceuticals as Wonderland 2022 Headline Sponsor

It’s an honor for Microdose to announce Algernon Pharmaceuticals as the Headline Sponsor for Wonderland: Miami 2022....

By Microdose

Industry

17 Oct 2022

Top Reasons To Be At Wonderland 2022 (Part 1)

Wonderland 2021 successfully established the event as the go-to industry gathering....

By Microdose

Industry

11 Oct 2022

American Psychedelic Practitioners Association (APPA) Launches Non-Profit

The American Psychedelic Practitioners Association (APPA) has announced the launch of their organization, establishing safe, ethical and accessible psychedelic therapy and specific focus Psychedelic Assisted Therapy (PAT)....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.